MicuRx Lands $9.6 Million to Fund China Trials of Antibiotic
MicuRx Pharma, a US-China clinical-stage biopharma, formed a JV with Shanghai Zhangjiang Biomedical Industry Venture Capital. Shanghai Zhangjiang invested 60 million RMB ($9.6 million) in the JV, and MicuRx contributed China rights to its lead antibiotic candidate. MRX-I is a novel, oral oxazolidinone antibiotic that is designed to be effective against antibiotic-resistant infections. MicuRx, which located its China facilities in Zhangjiang Park, will use the money to fund China Phase II and III clinical trials of MRX-I. More details... Share this with colleagues: var switchTo5x=true; stLight.options({publisher:'d7871f5b-67bc-4d30-b66f-1465d0b97213'});  
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here